Siegel RL, Miller KD, et al. Cancer statistics. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:4429–34.

Article  Google Scholar 

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.

Article  CAS  PubMed  Google Scholar 

Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol OncolJ Hematol Oncol. 2023;16:100.

Article  CAS  Google Scholar 

Al-Hajj M, Wicha MS, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ricci-Vitiani L, Lombardi DG, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.

Article  CAS  PubMed  Google Scholar 

O’Conor CJ, et al. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. Biomark Med. 2018;12(7):813–20.

Article  PubMed  Google Scholar 

Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. The Breast. 2015;24:S36-40.

Article  PubMed  Google Scholar 

Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–50.

Article  PubMed  PubMed Central  Google Scholar 

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin Cancer Res: Offic J Am Assoc for Cancer Res. 2014;20:782–90.

Article  CAS  Google Scholar 

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–98.

Article  CAS  PubMed  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428-440.e5.

Article  CAS  PubMed  Google Scholar 

Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA. 2015;112(6):1839–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560–4.

Article  CAS  PubMed  Google Scholar 

Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49:1476–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12:68–78.

Article  CAS  Google Scholar 

Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol. 2019;8:29.

Article  PubMed  PubMed Central  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:240–9.

Article  CAS  Google Scholar 

Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. Cancers. 2018;10:487.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;390:1949–61.

Article  CAS  Google Scholar 

Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282–8.

Article  PubMed  PubMed Central  Google Scholar 

Patsouris A, Tredan O, et al. RUBY: a phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). J Clin Oncol. 2019;37:1092–1092.

Article  Google Scholar 

Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol OncolJ Hematol Oncol. 2021;14:88.

Article  CAS  Google Scholar 

Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol OncolJ Hematol Oncol. 2019;12:94.

Article  Google Scholar 

Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.

Article  PubMed  PubMed Central  Google Scholar 

Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int J Biol Macromol. 2018;110:406–15.

Article  CAS  PubMed  Google Scholar 

Aditya B, Mayer IA, Vahdat LT, Tolaney SM, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.

Article